INDV — Indivior Pharmaceuticals Inc

Summary of Indivior Pharmaceuticals Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Net Revenue: $317 million, up 19% year-over-year.
• SUBLOCADE Net Revenue: $232 million, a 32% increase year-over-year, driven by a 20% growth in dispense units.
• Adjusted EBITDA: $164 million, reflecting a 112% year-over-year increase and a margin improvement of 23 percentage points.
• Cash Flow from Operations: Projected at approximately $340 million for 2026.
• Debt Management: Issued $500 million in convertible notes, reducing interest rates from 9.5% to 0.625%.

2. Strategic Updates and Business Highlights

• Consumer Campaign: The "Move Forward in Recovery" campaign is credited with increasing patient activation and driving new patient starts, which reached a record of approximately 31,800 in Q1.
• SUBLOCADE's Market Position: Remains the #1 prescribed long-acting injectable for opioid use disorder, with stable category share at 76%.
• R&D Pipeline Adjustments: INDV-6001 will not progress to Phase III, and INDV-2000 did not meet primary endpoints in Phase II trials. Focus will shift to external business development opportunities for INDV-2000.

3. Forward Guidance and Outlook

• Raised Financial Guidance for 2026:
  • Total net revenue expected between $1.215 billion and $1.285 billion.
  • SUBLOCADE net revenue projected at $950 million to $990 million, a 13% year-over-year increase.
  • Adjusted EBITDA forecasted between $620 million and $660 million, a 50% increase year-over-year.
• Growth Strategy: Focus on accelerating SUBLOCADE dispense unit growth to mid-teens and enhancing cash flow and adjusted EBITDA.

4. Bad News, Challenges, or Points of Concern

• R&D Setbacks: The discontinuation of INDV-6001 and INDV-2000 development raises concerns about the pipeline's robustness.
• Gross-to-Net Adjustments: Expected to serve as a headwind for both SUBLOCADE and SUBOXONE in 2026, impacting revenue.
• Market Competition: Potential competition from other companies, such as Lilly's brenipatide, could affect SUBLOCADE's long-term growth, although Indivior maintains confidence in its product's durability.

5. Notable Q&A Insights

• Gross Margins: Expected to remain in the mid-80% range, with Q1 benefiting from prior year releases and positive manufacturing variances.
• Business Development Focus: Indivior is open to acquiring commercial stage assets with a minimum peak sales potential of $200 million and is comfortable with leverage up to 3x.
• Patient Persistence: The accelerated second dosing of SUBLOCADE is believed to enhance early patient stabilization and long-term persistence, a key factor in treatment success.
• Overall Market Dynamics: The LAI category is growing, with SUBLOCADE maintaining a strong market position despite potential competitive pressures.

This summary encapsulates the key takeaways from Indivior's Q1 2026 earnings call, highlighting both the company's achievements and the challenges it faces moving forward.